Wellington Management Group LLP Grows Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Wellington Management Group LLP raised its holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 66.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 602,936 shares of the biopharmaceutical company's stock after acquiring an additional 241,512 shares during the period. Wellington Management Group LLP owned approximately 0.31% of Esperion Therapeutics worth $995,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. BOKF NA acquired a new stake in shares of Esperion Therapeutics in the second quarter valued at approximately $26,000. Xponance Inc. acquired a new stake in shares of Esperion Therapeutics in the 2nd quarter worth $28,000. Traphagen Investment Advisors LLC purchased a new position in shares of Esperion Therapeutics during the 3rd quarter worth $27,000. National Bank of Canada FI boosted its position in shares of Esperion Therapeutics by 115.9% during the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company's stock valued at $44,000 after acquiring an additional 10,225 shares during the last quarter. Finally, Sivia Capital Partners LLC purchased a new stake in shares of Esperion Therapeutics in the second quarter valued at about $44,000. 47.39% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on ESPR shares. StockNews.com downgraded shares of Esperion Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday, November 15th. The Goldman Sachs Group assumed coverage on shares of Esperion Therapeutics in a research report on Wednesday. They set a "neutral" rating and a $4.00 price target on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $6.00 price objective on shares of Esperion Therapeutics in a research report on Friday, December 13th. Cantor Fitzgerald started coverage on Esperion Therapeutics in a research note on Tuesday. They set an "overweight" rating and a $8.00 target price for the company. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research note on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $7.30.

Esperion Therapeutics Stock Up 0.9 %

NASDAQ ESPR traded up $0.02 during trading on Friday, hitting $2.19. The stock had a trading volume of 6,135,917 shares, compared to its average volume of 6,377,633. The company has a market capitalization of $431.51 million, a PE ratio of -3.42 and a beta of 1.01. The firm has a 50 day moving average price of $2.41 and a 200 day moving average price of $2.22. Esperion Therapeutics, Inc. has a twelve month low of $1.58 and a twelve month high of $3.94.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.